Enveric Biosciences, Inc.
ENVB
$1.22
$0.00980.81%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 44.63% | 56.26% | 52.26% | 19.08% | 6.39% |
| Total Depreciation and Amortization | -17.28% | -17.98% | -20.20% | -14.55% | -6.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -34.73% | -58.94% | -50.61% | 205.41% | 167.74% |
| Change in Net Operating Assets | -142.16% | -405.90% | -441.49% | 136.78% | 19.67% |
| Cash from Operations | 45.18% | 48.34% | 43.35% | 34.84% | 17.80% |
| Capital Expenditure | -- | 100.00% | 100.00% | 100.00% | 99.11% |
| Sale of Property, Plant, and Equipment | -- | -100.59% | -100.59% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -100.00% | 100.00% | 120.14% | 102.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -35.47% | -36.29% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 220.83% | 225.94% | -- | -65.51% | -240.21% |
| Cash from Financing | 671.31% | 707.06% | -5.47% | -39.48% | -107.39% |
| Foreign Exchange rate Adjustments | 153.00% | -159.73% | 98.03% | 118.69% | 87.70% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 99.70% | 93.18% | 67.25% | 32.05% | -4,295.68% |